For the quarter ending 2025-09-30, PCSA made $52,270 in revenue. -$3,436,573 in net income. Net profit margin of -6574.66%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development expenses | 1,661,646 | 2,447,286 | ||
| General and administrative expenses | 1,827,197 | 1,503,497 | ||
| Operating loss | -3,488,843 | -3,950,783 | ||
| Other income, net | 52,270 | 16,865 | ||
| Net loss | -3,436,573 | -3,933,918 | ||
| Net loss per common share - basic | -0.07 | -0.25 | ||
| Net loss per common share - diluted | -0.07 | -0.25 | ||
| Weighted average common shares used to compute net loss applicable to common shares - basic | 47,525,522 | 15,569,312 | ||
| Weighted average common shares used to compute net loss applicable to common shares - diluted | 47,525,522 | 15,569,312 | ||
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)